Innovative Prognostic Factors and Follow-Up of Localized Thoracic Malignancies
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 June 2024 | Viewed by 1716
Special Issue Editor
Special Issue Information
Dear Colleagues,
During the past several decades, the use of large-range therapies and restrictive tumor-based therapeutic strategies to treat thoracic malignancies have demonstrated huge limits in terms of oncological outcome and tolerability for patients. This has highlighted the major need for changes in treatment paradigms and for adopting a more personalized and precise therapeutic approach, customized according to tumor- and patient-related factors. Although thoracic malignancies, lung cancer in particular, remain leading causes of cancer-related death worldwide, significant improvements were observed in the management and survival of patients treated by tailored multidisciplinary therapies including surgery, radiation therapy and systemic treatments like targeted and immune therapies.
A challenge for multidisciplinary teams is to define the most appropriate indicators of prognosis and response to treatments, either to link to the tumor or its host. Notably, it requires the integration of mechanisms of cellular transformation and immune controls, metabolism in the broad sense, ranging from risk factors linked to lifestyle to that of the molecular mechanisms induced in tumor or immune cells. In addition, the heterogeneity of tumors should be considered, as it plays an important role in resistance to treatment and constitutes a limit to effective precision/personalized medicine. In addition, patient-tailored multidisciplinary management requires appropriate follow-up, which needs to be re-defined according to each type of malignancy and each case of patients, especially in rare tumors. The overall aim of this Special Issue is to establish original and relevant prognostic and theranostic factors, allowing the most adequate treatment assignment and choice of treatment sequence, in a wide range of thoracic malignancies. Authors will notably focus on multidisciplinary approaches, including surgical resection, neoadjuvant and adjuvant therapies, and associated follow-up requirements. We are pleased to invite you to contribute to our Special Issue entitled “Innovative prognostic factors and follow-up of localized thoracic malignancies”.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: the prognosis and oncological management of early- and late-stage lung cancers, mesothelioma, thymoma, pulmonary neuroendocrine tumors, and chest-wall sarcoma. Among thoracic malignancies, analyses of rare tumors are particularly appreciated. Manuscripts addressing innovative methods of early postoperative and long-term follow-up are also welcome. We look forward to receiving your contributions.
Dr. Ludovic Fournel
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- prognosis
- lung cancer
- thoracic oncology
- mesothelioma
- neuroendocrine tumors
- thymoma
- sarcoma
- surgery
- multimodal treatment
- rare tumors
